Research programme: engineered chimeric antigen receptor-natural killer cell therapies - Deverra Therapeutics
Latest Information Update: 06 Oct 2022
At a glance
- Originator Deverra Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 04 Oct 2022 Deverra therapeutics has patent pending for Nk cell composition and preparations for immunotherapy and methods for their production
- 04 Oct 2022 Preclinical trials in Haematological malignancies in USA (Parenteral) (Deverra Therapeutics pipeline, October 2022)
- 04 Oct 2022 Preclinical trials in Solid tumours in USA (Parenteral) (Deverra Therapeutics pipeline, October 2022)